OUR PLATFORMS
Rooted in decades of experience in molecular biology, deep understandings of molecular diagnostics, and a wide range of OMICs technologies, Complete Omics has been working with world’s leaders in cancer proteomics and cancer genomics. Throughout the past decade, Complete Omics has established several robust platforms meeting the most demanding yet critical needs from basic research and clinical applications. We are well equipped to help you with your projects through our following patented or proprietary platforms:
Genomics
Patented DEEPER-Seq Platform — the world’s only barcoded single-strand library PLUS dual-RNA probe capture approach
Proteomics
Patented MT-SRM, SAFE-SRM, MANA-SRM, Neo-True Platforms — world’s leading authority in quantitative proteomics
Metabolomics
Proprietary MetaBoost chemical derivatizations for extremely sensitive detection and quantification of small molecules.
Please click on each specific technology above to learn more about Complete Omics’ expertise and our vision in clinical applications…
PIONEERING IN MULTI-OMICS CANCER DIAGNOSTICS SINCE 2010
In 2010, Dr. Qing Wang reported the 1st pipeline for detecting mutant proteins as cancer-specific biomarkers through Mass Spectrometry following NGS (next-generation sequencing)-based identification of personalized mutations (PNAS). Throughout the past 10 years, we have been pioneering the developments of clinical multi-omics technologies including the 1st clinical proteomics-based ovarian cancer diagnostic platform (PNAS), the 1st personalized cancer neoantigen therapeutic target detection and quantification platform (Science; Science Immunology; Science Advances), the most in-depth plasma proteomics pipeline (quantifying 4,550 proteins in plasma), the world’s only dual-RNA probe-based targeted NGS pipeline (DEEPER-Seq), etc. Backed by top publication records, we are looking for active clinical collaborators to test our clinical platforms. Any clinical project is welcome if it is addressing a pressing clinical need. BTW, Collaborations are Completely FREE! Just ask.
Complete360® Enables Deep Biomarker Profiling in Groundbreaking iPSC CAR‑NK Cell Therapy Study Published in Cell
June 25, 2025 | BALTIMORE – We are thrilled to share that a major milestone in cell therapy has just been published in Cell, showcasing the world’s first-in-human clinical study of dual-targeting CAR-NK cells derived from induced pluripotent stem cells (iPSCs). The therapy demonstrated promising efficacy with an excellent safety profile—no signs of cytokine release syndrome (CRS), neurotoxicity, or graft-versus-host disease (GvHD). This represents a paradigm shift toward scalable, off-the-shelf immune cell therapy solutions. — But what powers the safety, monitoring, and mechanistic understanding behind such a novel therapy? The answer lies in Complete360®, our proprietary clinical-grade deep plasma proteomics platform.
Complete Omics Makes Landmark Debut at ASMS 2025
June 5, 2025 | BALTIMORE -Complete Omics Inc. is proud to announce a successful debut at the American Society for Mass Spectrometry (ASMS) 2025 Annual Meeting, held in Baltimore, Maryland.
Milestone! | Complete Omics Inc. Secures California Clinical Laboratory License, Expanding Access to Cutting-Edge Clinical Proteomics Testing
Feb 20, 2025 | BALTIMORE – Complete Omics Inc., a leader in clinical proteomics and multi-omics molecular diagnostics, proudly announces its recent achievement of the California Clinical Laboratory License. This milestone marks a pivotal expansion in the company’s ability to serve patients and healthcare providers across California, the most populous state in the U.S.
“We see each individual as an integrity of multiple universes. We are striving to provide the most sensitive and specific health surveillance tests through measuring the individual’s different pools of biological molecules simutaneously.”
— Qing Wang, Founder and CEO
Our People | check here for the team of Complete Omics |
Complete Omics is incorporated by a vibrant team of excellent scientists. With decades of expertises in molecular diagnostics and Omics-based technologies, our scientists and directors are building something fantastic for human population. We are hiking alone, but are determined to change the world!
2023–Closing latest financing round with QiMing Venture Partners
Complete Omics proudly announces its latest financing round’s success, significantly backed by Qiming Venture Partners, China’s top healthcare VC. This achievement is particularly remarkable given the current economic climate, where securing investment has become increasingly challenging, especially in the healthcare and pharmaceutical sectors. Our team’s dedication and resilience have been key in reaching this pivotal moment for our company. Our collaboration with Qiming, known for investing in industry leaders like Xiaomi (1810.HK), Meituan (3690.HK), and Bilibili (BILI), signals strong confidence in our mission and future. This investment propels us into new realms of innovation in clinical proteomics and molecular diagnostics, underscoring our commitment to transforming healthcare. It positions us among influential firms, promising a future of growth and breakthroughs despite the economic slowdown. We’re excited for what’s ahead and invite our community to join us in this journey towards significant healthcare advancements. Together, we’re poised to redefine the landscape of personalized medicine. (Ref. 1, 2).A Proud Partner of QiMing VC
Latest News
Complete360® Enables Deep Biomarker Profiling in Groundbreaking iPSC CAR‑NK Cell Therapy Study Published in Cell
June 25, 2025 | BALTIMORE – We are thrilled to share that a major milestone in cell therapy has just been published in Cell, showcasing the world’s first-in-human clinical study of…
Complete Omics Makes Landmark Debut at ASMS 2025
June 5, 2025 | BALTIMORE -Complete Omics Inc. is proud to announce a successful debut at the American Society for Mass Spectrometry (ASMS) 2025 Annual Meeting, held in Baltimore, Maryland.
Milestone! | Complete Omics Inc. Secures California Clinical Laboratory License, Expanding Access to Cutting-Edge Clinical Proteomics Testing
Feb 20, 2025 | BALTIMORE – Complete Omics Inc., a leader in clinical proteomics and multi-omics molecular diagnostics, proudly announces its recent achievement of the California Clinical Laboratory License. This…
